HLA-A*0201 T-cell epitopes in severe acute respiratory syndrome (SARS) coronavirus nucleocapsid and spike proteins

Biochemical and Biophysical Research Communications

Volumn 344, Issue 1, 2006, Pages 63-71

  Tsao, Yeou Ping ^a,c   Lin, Jian Yu ^a,c   Jan, Jia Tsrong ^a,c   Leng, Chih Hsiang ^b,c   Chu, Chen Chung ^c   Yang, Yuh Cheng ^c   Chen, Show Li ^a,c,d  

^a NATIONAL DEFENSE MEDICAL CENTER   (Taiwan)

^b NATIONAL HEALTH RESEARCH INSTITUTES   (Taiwan)

^c MACKAY MEMORIAL HOSPITAL   (Taiwan)

^d NATIONAL TAIWAN UNIVERSITY   (Taiwan)

Author keywords

CTL epitope; HLA A*0201; Nucleocapsid; SARS virus; Spike

Indexed keywords

EPITOPE; GAMMA INTERFERON; HLA A ANTIGEN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; NUCLEOCAPSID PROTEIN; T LYMPHOCYTE ANTIGEN; VIRUS SPIKE PROTEIN; CPG ODN 1826; DNA; HLA A*0201 ANTIGEN; HLA A2 ANTIGEN; HLA-A*0201 ANTIGEN; MEMBRANE PROTEIN; NUCLEOCAPSID PROTEIN, CORONAVIRUS; PEPTIDE; SPIKE GLYCOPROTEIN, CORONAVIRUS; VIRUS ENVELOPE PROTEIN; VIRUS VACCINE;

ALLELE; AMINO TERMINAL SEQUENCE; ANIMAL CELL; ARTICLE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DRUG BINDING; DRUG EFFICACY; DRUG IDENTIFICATION; DRUG SCREENING; HUMAN; HUMAN CELL; IMMUNOGENICITY; MOUSE; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PREDICTION; PRIORITY JOURNAL; PROTEIN BINDING; SARS CORONAVIRUS; STIMULATION; T LYMPHOCYTE; TRANSGENIC MOUSE; VALIDATION PROCESS; ANIMAL; CHEMISTRY; GENETICS; IMMUNOLOGY; MOLECULAR GENETICS; MONONUCLEAR CELL; SEVERE ACUTE RESPIRATORY SYNDROME; TH2 CELL; VIRUS CAPSID;

ANIMALIA; CORONAVIRUS; MIRIDAE; MUS MUSCULUS; SARS CORONAVIRUS;

ANIMALS; CAPSID; DNA; EPITOPES, T-LYMPHOCYTE; HLA-A ANTIGENS; HLA-A2 ANTIGEN; HUMANS; LEUKOCYTES, MONONUCLEAR; MEMBRANE GLYCOPROTEINS; MICE; MICE, TRANSGENIC; MOLECULAR SEQUENCE DATA; NUCLEOCAPSID PROTEINS; PEPTIDES; SARS VIRUS; SEVERE ACUTE RESPIRATORY SYNDROME; T-LYMPHOCYTES, CYTOTOXIC; TH2 CELLS; VIRAL ENVELOPE PROTEINS; VIRAL VACCINES;

EID: 33646058584     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2006.03.152     Document Type: Article

References (40)

1. Ksiazek G., Endman D., Goldsmith C.S., Zaki S.R., Peret T., Emery S., Tong S., Urbani C., Comer J.A., Lim W., Rollin P.E., Dowell S.F., Ling A.E., Humphrey C.D., Shieh W.J., Guarner J., Paddock C.D., Rota P., Fields B., DeRisi J., Yang J.Y., Cox N., Hughes J.M., LeDuc J.W., Bellini W.J., Anderson L.J., and Group S.W. A novel coronavirus associated with severe acute respiratory syndrome. N. Engl. J. Med. 348 (2003) 1953-1966
2. Poutanen M., Low E., Henry B., Finkelstein S., Rose D., Green K., Tellier R., Draker R., Adachi D., Ayers M., Chan A.K., Skowronski D.M., Salit I., Simor A.E., Slutsky A.S., Doyle P.W., Krajden M., Petric M., Brunham R.C., McGeer A.J., C. National Microbiology Laboratory, and C. S. A. R. S. S. Team. Identification of severe acute respiratory syndrome in Canada. N. Engl. J. Med. 56 (2003) 582-588
3. Ruan Y.J., Wei C.L., Ee L.A., Vega V.B., Thoreau H., Su S.T., Chia J.M., Ng P., Chiu K.P., Lim L., Zhang T., Peng C.K., Lin E.O., Lee N.M., Yee S.L., Ng L.F., Chee R.E., Stanton L.W., Long P.M., and Liu E.T. Comparative full-length genome sequence analysis of 14 SARS coronavirus isolates and common mutations associated with putative origins of infection. Lancet 361 (2003) 1779-1785
4. Li W., Moore M.J., Vasilieva N., Sui J., Wong S.K., Berne M.A., Somasundaran M., Sullivan J.L., Luzuriaga K., Greenough T.C., Choe H., and Farzan M. Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus. Nature 426 (2003) 450-454
5. Pei J., Briles W.E., and Collisson E.W. Memory T cells protect chicks from acute infectious bronchitis virus infection. Virology 306 (2003) 376-384
6. Seo S.H., Wang L., Smith R., and Collisson E.W. The carboxyl-terminal 120-residue polypeptide of infectious bronchitis virus nucleocapsid induces cytotoxic T lymphocytes and protects chickens from acute infection. J. Virol. 71 (1997) 7889-7894
7. *0201-restricted E7-encoded epitope. Cancer Res. 56 (1996) 582-588
8. + T-cell epitopes. Blood 99 (2002) 2100-2106
9. Wolfel T., Van Pel A., Brichard V., Schneider J., Seliger B., Meyer zum Buschenfelde K.H., and Boon T. Two tyrosinase nonapeptides recognized on HLA-A2 melanomas by autologous cytolytic T lymphocytes. Eur. J. Immunol. 24 (1994) 759-764
10. Liu S.J., Leng C.H., Lien S.P., Chi H.Y., Huang C.Y., Lin. C.L., Lian W.C., Chen C.J., Hsieh S.L., and Chong P. Immunological characterizations of the nucleocapsid protein based SARS vaccine candidates. Vaccine 24 (2006) 3100-3108
11. Bullock T.N., Colella T.A., and Engelhard V.H. The density of peptides displayed by dendritic cells affects immune responses to human tyrosinase and gp100 in HLA-A2 transgenic mice. J. Immunol. 164 (2000) 2354-2361
12. Lin C.W., Lee J.Y., Tsao Y.P., Shen C.P., Lai H.C., and Chen S.L. Oral vaccination with recombinant Listeria monocytogenes expressing human Papillomavirus type 16 E7 can regress tumor growth in mice. Int. J. Cancer 298 (2002) 805-814
13. + T cells to severe acute respiratory syndrome (SARS) coronavirus in recovered SARS patients and healthy individuals. J. Immunol. 175 (2005) 591-598
14. Lin M., Chu C.C., Lee H.L., Chang S.L., Ohashi J., Tokunaga K., Akaza T., and Juji T. Heterogeneity of Taiwan's indigenous population: possible relation to prehistoric Mongoloid dispersals. Tissue Antigens 55 (2000) 1-9
15. Kaufmann A.M., Nieland J., Schinz M., Nonn M., Gabelsberger J., Meissner H., Muller R.T., Jochmus I., Gissmann L., Schneider A., and Durst M. HPV16 L1E7 chimeric virus-like particles induce specific HLA-restricted T cells in humans after in vitro vaccination. Int. J. Cancer 92 (2001) 285-293
16. Hsueh P.R., and Yang P.C. Severe acute respiratory syndrome epidemic in Taiwan. J. Microbiol. Immunol. Infect. 38 (2005) 82-88
17. Vigneau S., Rohrlich P.S., Brahic M., and Bureau J.F. Tmevpg1, a candidate gene for the control of Theiler's virus persistence, could be implicated in the regulation of gamma interferon. J. Virol. 77 (2003) 5632-5638
18. Chen Y.F., Lin C.W., Tsao Y.P., and Chen S.L. Cytotoxic-T-lymphocyte human papillomavirus type 16 E5 peptide with CpG-oligodeoxynucleotide can eliminate tumor growth in C57BL/6 mice. J. Virol. 78 (2004) 1333-1343
19. Evans C., Bauer S., Grubert T., Brucker C., Baur S., Heeg K., Wagner H., and Lipford G.B. HLA-A2-restricted peripheral blood cytolytic T lymphocyte response to HPV type 16 proteins E6 and E7 from patients with neoplastic cervical lesions. Cancer Immunol. Immunother. 42 (1996) 151-160
20. Nakagawa M., Stites D.P., Farhat S., Sisler J.R., Moss B., Kong F., Moscicki A.B., and Palefsky J.M. Cytotoxic T lymphocyte responses to E6 and E7 proteins of human papillomavirus type 16: relationship to cervical intraepithelial neoplasia. J. Infect. Dis. 175 (1997) 927-931
21. Borysiewicz L.K., Fiander A., Nimako M., Man S., Wilkinson G.W., Westmoreland D., Evans A.S., Adams M., Stacey S.N., Boursnell M.E., Rutherford E., Hickling J.K., and Inglis S.C. A recombinant vaccinia virus encoding human papillomavirus types 16 and 18, E6 and E7 proteins as immunotherapy for cervical cancer. Lancet 347 (1996) 1523-1527
22. Schreurs M.W., Scholten K.B., Kueter E.W., Ruizendaal J.J., Meijer C.J., and Hooijberg E. In vitro generation and life span extension of human papillomavirus type 16-specific, healthy donor-derived CTL clones. J. Immunol. 171 (2003) 2912-2921
23. Rivoltini L., Loftus D.J., Barracchini K., Arienti F., Mazzocchi A., Biddison W.E., Salgaller M.L., Appella E., Parmiani G., and Marincola F.M. Binding and presentation of peptides derived from melanoma antigens MART-1 and glycoprotein-100 by HLA-A2 subtypes. Implications for peptide-based immunotherapy. J. Immunol. 156 (1996) 3882-3891
24. + T-cell epitope SSp-1 of SARS-CoV spike protein. Blood 104 (2004) 200-206
25. Wang Y.D., Sin W.Y., Xu G.B., Yang H.H., Wong T.Y., Pang X.W., He X.Y., Zhang H.G., Ng J.N., Cheng C.S., Yu J., Meng L., Yang R.F., Lai S.T., Guo Z.H., Xie Y., and Chen W.F. T-cell epitopes in severe acute respiratory syndrome (SARS) coronavirus spike protein elicit a specific T-cell immune response in patients who recover from SARS. J. Virol. 78 (2004) 5612-5618
26. Huang L.R., Chiu C.M., Yeh S.H., Huang W.H., Hsue P.R., Yang W.Z., Yang J.Y., Su I.J., Chang S.C., and Chen P.J. Evaluation of antibody responses against SARS coronaviral nucleocapsid or spike proteins by immunoblotting or ELISA. J. Med. Virol. 73 (2004) 338-346
27. Leung D.T., Tam F.C., Ma C.H., Chan P.K., Cheung J.L., Niu H., Tam J.S., and Lim P.L. Antibody response of patients with severe acute respiratory syndrome (SARS) targets the viral nucleocapsid. J. Infect. Dis. 190 (2004) 379-386
28. Daginakatte G.C., Chard-Bergstrom C., Andrews G.A., and Kapil S. Production, characterization, and uses of monoclonal antibodies against recombinant nucleoprotein of elk coronavirus. Clin. Diagn. Lab. Immunol. 6 (1999) 341-344
29. Ndifuna A., Waters A.K., Zhou M., and Collisson E.W. Recombinant nucleocapsid protein is potentially an inexpensive, effective serodiagnostic reagent for infectious bronchitis virus. J. Virol. Methods 70 (1998) 37-44
30. Gao W., Tamin A., Soloff A., Aiuto L.D., Nwanegbo E., Robbins P.D., Bellini W.J., Barratt-Boyes S., and Gambotto A. Effects of a SARS-associated coronavirus vaccine in monkeys. Lancet (2003) 1895-1896
31. Jin H., Xiao C., Chen Z., Kang Y., Ma Y., Zhu K., Xie Q., Tu Y., Yu Y., and Wang B. Induction of Th1 type response by DNA vaccinations with N, M, and E genes against SARS-CoV in mice. Biochem. Biophys. Res. Commun. 328 (2005) 979-986
32. Rota P.A., Oberste M.S., Monroe S.S., Nix W.A., Campagnoli R., Icenogle J.P., Penaranda S., Bankamp B., Maher K., Chen M.H., Tong S., Tamin A., Lowe L., Frace M., DeRisi J.L., Chen Q., Wang D., Erdman D.D., Peret T.C., Burns C., Ksiazek T.G., Rollin P.E., Sanchez A., Liffick S., Holloway B., Limor J., McCaustland K., Olsen-Rasmussen M., Fouchier R., Gunther S., Osterhaus A.D., Drosten C., Pallansch M.A., Anderson L.J., and Bellini W.J. Characterization of a novel coronavirus associated with severe acute respiratory syndrome. Science 300 (2003) 1394-1399
33. Buchholz U.J., Bukreyev A., Yang L., Lamirande E.W., Murphy B.R., Subbarao K., and Collins P.L. Contributions of the structural proteins of severe acute respiratory syndrome coronavirus to protective immunity. Proc. Natl. Acad. Sci. USA 101 (2004) 9804-9809
34. He Y., Zhou Y., Liu S., Kou Z., Li W., Farzan M., and Jiang S. Receptor-binding domain of SARS-CoV spike protein induces highly potent neutralizing antibodies: implication for developing subunit vaccine. Biochem. Biophys. Res. Commun. 324 (2004) 773-781
35. Sui J., Li W., Murakami A., Tamin A., Matthews L.J., Wong S.K., Moore M.J., Tallarico A.S., Olurinde M., Choe H., Anderson L.J., Bellini W.J., Farzan M., and Marasco W.A. Potent neutralization of severe acute respiratory syndrome (SARS) coronavirus by a human mAb to S1 protein that blocks receptor association. Proc. Natl. Acad. Sci. USA 101 (2004)
36. Wong S.K., Li W., Moore M.J., Choe H., and Farzan M. A 193-amino acid fragment of the SARS coronavirus S protein efficiently binds angiotensin-converting enzyme 2. J. Biol. Chem. 279 (2004) 3197-3201
37. Hua R., Zhou Y., Wang Y., Hua Y., and Tong G. Identification of two antigenic epitopes on SARS-CoV spike protein. Biochem. Biophys. Res. Commun. 319 (2004) 929-935
38. Krokhin O., Li Y., Andonov A., Feldmann H., Flick R., Jones S., Stroeher U., Bastien N., Dasuri K.V., Cheng K., Simonsen J.N., Perreault H., Wilkins J., Ens W., Plummer F., and Standing K.G. Mass spectrometric characterization of proteins from the SARS virus: a preliminary report. Mol. Cell Proteomics 2 (2003) 346-356
39. Zhong X., Yang H., Guo Z.F., Sin W.Y., Chen W., Xu J., Fu L., Wu J., Mak C.K., Cheng C.S., Yang Y., Cao S., Wong T.Y., Lai S.T., Xie Y., and Guo Z. B-cell responses in patients who have recovered from severe acute respiratory syndrome target a dominant site in the s2 domain of the surface spike glycoprotein. J. Virol. 79 (2005) 3401-3408
40. Chen Z., Zhang L., Qin C., Ba L., Yi C.E., Zhang F., Wei Q., He T., Yu W., Yu J., Gao H., Tu X., Gettie A., Farzan M., Yuen K.Y., and Ho D.D. Recombinant modified vaccinia virus ankara expressing the spike glycoprotein of severe acute respiratory syndrome coronavirus induces protective neutralizing antibodies primarily targeting the receptor binding region. J. Virol. 79 (2005) 2678-2688